Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z8CQ
|
||||
| Drug Name |
Sarilumab
|
||||
| Synonyms |
Kevzara
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Severely active rheumatoid arthritis [ICD10:M05-M06] | Approved | [1] | ||
| Company |
Sanofi Synthelabo
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-6 receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| HIF-1 signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| Jak-STAT signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Reactome | MAPK3 (ERK1) activation | ||||
| MAPK1 (ERK2) activation | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Senescence and Autophagy in Cancer | |||||
| IL-6 signaling pathway | |||||
| Differentiation Pathway | |||||
| Interleukin-6 signaling | |||||
| References | |||||
| REF 1 | Drugs@FDA (Edaravone) | ||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.